Alligator Bioscience
Scheelevägen 19 A
Lund
223 70
Tel: 46-0-46-286-4280
Fax: 46-0-46-286-4290
Website: http://www.alligatorbioscience.com/
Email: info@alligatorbioscience.com
122 articles about Alligator Bioscience
-
Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
8/18/2021
Alligator Bioscience announced that the company has entered into a research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop together new bispecific antibody cancer therapeutics
-
Alligator Bioscience Announces New Senior Director of Communications & Investor Relations
8/16/2021
Alligator Bioscience today announced that Julie Silber has joined the company as the new Senior Director of Communications and Investor Relations.
-
Alligator Bioscience AB: Interim report January-June 2021
7/13/2021
As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on the company have been surpassed already.
-
Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data
6/30/2021
Alligator Bioscience and Scandion Oncology announces promising preclinical data from their ongoing collaboration exploring the anti-tumor effects on drug resistant cancer by combining Scandion Oncology's drug candidate SCO-101 and Alligator Bioscience's candidate drug mitazalimab.
-
Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy
6/7/2021
Alligator Bioscience announces that the scientific journal Expert Opinion on Biological Therapy has published an article by scientists at Alligator Bioscience, reviewing the field of CD40 agonistic antibodies.
-
Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017
6/4/2021
Alligator Bioscience presents novel supportive data from the ongoing Phase I clinical trial with the 4-1BB drug candidate ATOR-1017 developed as tumor-directed therapy for metastatic cancer.
-
Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021
6/1/2021
Alligator Bioscience, announces that the annual general meeting was held in the company this day.
-
Alligator's mitazalimab shown to enhance cancer vaccine
5/5/2021
Alligator Bioscience announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy.
-
Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field
5/4/2021
Alligator Bioscience announced that it has entered into a joint research agreement with BioArctic AB, a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
-
Alligator Bioscience AB: Interim report January-March 2021
4/27/2021
So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year.
-
The Nomination Committee's proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB
4/22/2021
Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021 , the Nomination Committee announces its proposals regarding Chairman of the board, Vice Chairman of the board and other board members.
-
Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
4/15/2021
Alligator Bioscience announced that it has entered into a joint research collaboration with MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
-
Alligator Bioscience postpones the Annual General Meeting to June 1, 2021
4/3/2021
Alligator Bioscience announced that the board of directors has decided to postpone the Annual General Meeting to June 1, 2021, in connection with that Søren Bregenholt takes office as new CEO of Alligator.
-
Alligator Bioscience publishes Annual Report for 2020
3/18/2021
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been published. The Annual Report is attached as a PDF and is available on the company's website, https://alligatorbioscience.se/en/investors/financial-reports/
-
Alligator Bioscience appoints Søren Bregenholt as new CEO
3/18/2021
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søren Bregenholt, Ph.D. as the company's new Chief Executive Officer (CEO), to strengthen Alligator's business development activities and clinical progress on an international level.
-
Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR
3/11/2021
Alligator Bioscience announced that an abstract for a poster presentation at the AACR Annual Meeting 2021, presenting new preclinical data for the clinical asset mitazalimab, is now released.
-
Alligator Bioscience AB: Year-end Report January-December 2020
2/26/2021
Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer.
-
Alligator Bioscience recruits new Chief Medical Officer
12/29/2020
Alligator Bioscience announced that the company has appointed Dr Christina Reimer as Chief Medical Officer.
-
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
12/28/2020
Alligator Bioscience announced that it has submitted a CTA application to the relevant regulatory authorities to start a Phase II efficacy study of its wholly-owned CD40 targeting antibody mitazalimab.
-
Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library
12/10/2020
Alligator Bioscience announced the completion of a novel proprietary human synthetic antibody library in Fab format - ALLIGATOR-FAB™.